Vasculitis and hereditary small vessel diseases;Vaskulitis und genetisch bedingte Mikroangiopathien

Internist

Volumn 50, Issue 11, 2009, Pages 1200-1209

  Opherk, C ^a   Peters, N ^a   Dichgans, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CADASIL; Cerebral vasculitis; MELAS; Morbus fabry; Small vessel disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DONEPEZIL; ERGOT DERIVATIVE; GALACTOSIDASE; INFLIXIMAB; METHOTREXATE; PREDNISONE; RITUXIMAB; STATIN; STEROID; TRIPTAN DERIVATIVE;

BIOPSY; BRAIN; BRAIN VASCULITIS; CADASIL; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; FABRY DISEASE; FAMILY HISTORY; GENETIC ANALYSIS; GENETIC COUNSELING; HUMAN; LABORATORY TEST; MAINTENANCE THERAPY; MIGRAINE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; STROKE;

HUMANS; PERIPHERAL VASCULAR DISEASES; STROKE; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 70449529786     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-009-2469-9     Document Type: Review

References (30)

1. Appenzeller S, Costallat LT, Cendes F (2006) Neurolupus. Arch Neurol 63:458-460
2. Berlit P (2004) Diagnose und Differenzialdiagnose der zerebralen Vaskulitis. Nervenarzt 75:105-112
3. Berlit P (2004) Zerebrale Vaskulitis. Nervenarzt 75: 817-828
4. Berlit P (2009) Primary angiitis of the CNS - an enigma that needs world-wide efforts to be solved. Eur J Neurol 16:10-11
5. 5. Calabrese LH, Dodick DW, Schwedt TJ et al. (2007) Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 146:34-44 (Pubitemid 351650319)
6. Chabriat H, Joutel A, Dichgans M et al. (2009) CADASIL. Lancet Neurol 8:643-653
7. Dichgans M, Markus HS, Salloway S et al. (2008) Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 7:310-318
8. 8. Dichgans M, Mayer M, Uttner I et al. (1998) The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 44:731-739 (Pubitemid 28516043)
9. Dichgans M, Petersen D (1997) Angiographic complications in CADASIL. Lancet 349:776-777
10. 10. Gottenberg JE, Guillevin L, Lambotte O et al. (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:913-920 (Pubitemid 40733918)
11. Hajj-Ali RA, Calabrese LH (2009) Central nervous system vasculitis. Curr Opin Rheumatol 21:10-18
12. Hara K, Shiga A, Fukutake T et al. (2009) Association of HTRAl mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360: 1729-1739
13. Herrlinger U, Dichgans M (2007) Vaskulitiden des ZNS. In: Brandt D, Dichgans J, Diener HC (Hrsg) Therapie und Verlauf neurologischer Erkrankungen. Kohlhammer, Stuttgart
14. 14. Joutel A, Andreux F, Gaulis S et al. (2000)The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 105:597-605 (Pubitemid 30146506)
15. 15. Joutel A, Corpechot C, Ducros A et al. (1996) Notch3 mutations in CADASIL, a hereditary adultonset condition causing stroke and dementia. Nature 383:707-710 (Pubitemid 26360644)
16. Keogh KA, Ytterberg SR, Fervenza FC et al. (2006) Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180-187
17. 17. Maclaren K, Gillespie J, Shrestha S et al. (2005) Primary angiitis of the central nervous system: emerging variants. QJM 98:643-654 (Pubitemid 41236093)
18. 18. Opherk C, Peters N, Herzog J et al. (2004) Longterm prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain 127: 2533-2539 (Pubitemid 39472981)
19. 19. Opherk C, Peters N, Holtmannspotter M et al. (2006) Heritability of MRI lesion volume in CADASIL: evidence for genetic modifiers. Stroke 37: 2684-2689 (Pubitemid 44922526)
20. 20. Peters N, Herzog J, Opherk C et al. (2004) A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke 35: 1603-1608 (Pubitemid 38823633)
21. 21. Peters N, Opherk C, Bergmann T et al. (2005) Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol 62: 1091-1094 (Pubitemid 41043729)
22. 22. Peters N, Opherk C, Danek A et al. (2005) The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. Am J Psychiatry 162:2078-2085 (Pubitemid 41598261)
23. Pfefferkorn T, Bitterling H, Hufner K et al. (2008) Malignant hemispheric infarction in Takayasu arteritis. J Neurol 255:1425-1426
24. 24. Richards A, Van Den Maagdenberg AM, Jen JC et al. (2007) C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 39:1068-1070 (Pubitemid 47340644)
25. 25. Rolfs A, BottcherT, Zschiesche M et al. (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794-1796 (Pubitemid 41642643)
26. Sproule DM, Kaufmann P (2008) Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann N Y Acad Sci 1142:133-158
27. Tanaka F, Kawakami A, Iwanaga N et al. (2006) Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 45:313-316
28. Topakian R, Stieglbauer K, Nussbaumer K et al. (2008) Cerebral vasculitis and stroke in Lyme neuroborreliosis.Two case reports and review of current knowledge. Cerebrovasc Dis 26:455-461
29. 29. Watts R, Lane S, HanslikT et al. (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculites and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222-227 (Pubitemid 46226058)
30. Younger DS (2004) Vasculitis of the nervous system. Curr Opin Neurol 17:317-336